Lenvat 4 (Lenvatinib) 4 mg

Approved for:

• Hepatocellular Carcinoma (HCC): Unresectable liver cancer (First-line).
• Differentiated Thyroid Cancer (DTC): Progressive, radioiodine-refractory.
• Renal Cell Carcinoma (RCC): Advanced kidney cancer (with Everolimus).

Strength: 4 mg per capsule.

Common Dosing Scenarios:

• Liver Cancer (< 60 kg body weight): 8 mg (2 capsules) once daily.
• Liver Cancer (≥ 60 kg body weight): 12 mg (3 capsules) once daily.
• Dose Reduction: If toxicity occurs at high doses (e.g., 24 mg), the doctor may reduce the dose to 20 mg, 14 mg, or 10 mg using combinations of capsules.

⚠️ Instruction: Swallow whole with water. Do not open or crush.

• Uncontrolled Hypertension.
• Severe hepatic impairment.
• Pregnancy and breastfeeding.
• History of gastrointestinal fistula.

Adverse events are common:

• Hypertension: Monitor blood pressure daily.
• Proteinuria: Regular urinalysis is required.
• Hand-Foot Syndrome: Redness/pain on palms and soles.
• Fatigue and Diarrhea.